Article: Pharmacology Update: Risedronate (Actonel)-A New Weekly Option for Osteoporosis.(Drug overview)

Pharmacology Update

Risedronate (Actonel)A New Weekly Option for Osteoporosis

By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD

Risedronate has been approved in a 35 mg once weekly formulation for the treatment of osteoporosis. The drug is currently available as a 5 mg once daily product, but because the drug requires special precautions when it is taken, the once-a-week form may be more convenient. Alendronate (Fosamax), the other currently available oral bisphosphonate, is also available in a once a day and once a week formulation. Risedronate is marketed as Actonel by Proctor & Gamble and Aventis Pharmaceuticals.

...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!